Maine Chapter

INCORPORATED IN MAINE



Executive Committee

President Brian Youth, MD, FAAP

Vice President Anne Coates, MD, FAAP

Treasurer Jeffrey Stone, DO, FAAP

Secretary Genevieve Whiting, MD, FAAP

Immediate Past President Laura Blaisdell, MD, MPH, FAAP

Board of Directors

Joseph Anderson, DO, FAAP Rebecca Brakeley, MD, FAAP Amy Buczkowski, MD, FAAP Melissa Burch, MD, FAAP Adrienne Carmack, MD, FAAP Gabriel Civiello, MD, FAAP Alyssa Goodwin, MD, FAAP Allison Grover, MD* Deborah Q. Hagler, MD, MPH, FAAP Dan Hale, MD, FAAP Jennifer Jewell, MD, MS, FAAP Stephanie Joy, MD, FAAP Emily Keller, MD, FAAP Alton Kremer, MD, PhD, FAAP Michele LaBotz, MD, FAAP Lawrence Losey, MD, FAAP Sophia Martens** Christopher Motyl, DO, FAAP Valerie O'Hara, DO, FAAP Calvin Schaffer, MD* Andrea Tracy, MD, FAAP Lara Walsh, MD, FAAP Afnan Yahya** Margaret Zamboni, DO, FAAP

*Resident Board Representatives

Staff

Dee Kerry, BS Executive Director

Emily Belanger, RN, BSN Education & Membership Manager

Madeleine DesFosses, BA
Public Health & Advocacy Manager

Tiffany Harrington, MBA
Development Director

30 Association Drive, Box 190 Manchester, ME 04351 office: 207-622-3374

Testimony in SUPPORT of LD 1734, An Act to Exempt Over-the-counter Medicines from the Sales and Use Tax

Committee on Taxation May 14, 2025

Senator Grohoski, Representative Cloutier, and Esteemed Members of the Taxation Committee,

My name is Madeleine DesFosses, and I am submitting this testimony on behalf of the Maine Chapter of the American Academy of Pediatrics. We are in support of LD 1734, which will help to make over-the-counter (OTC) medications more affordable for Maine families.

In Maine, prescription medications are currently tax-exempt, as they are considered essential. However, over-the-counter medications are also essential, but are subjected to the 5.5% general sales tax, which may be burdensome and prohibitive for many families in Maine. OTC medications may be needed to treat or relieve the symptoms of a cold that lasts only a few days, or may be needed for a long-term or chronic condition that an individual needs to use for months, years, or their lifetime. No matter the situation, individuals and families deserve to access medications at the lowest cost possible.

For a family struggling financially, the cost of OTC medications can be insurmountable. For example, for the OTC allergy medication Claritin costs 35 dollars before tax for a 45-count bottle, an amount that is simply unaffordable for many Mainers no matter how much they may need the medication. To make matters worse, the federal government is considering tariffs on imported medications, which could increase prices and worsen the financial burden placed on families.

Accessible and affordable OTC medications not only save Maine families money, but also saves our healthcare system dollars. In fact, it is estimated that every 1 dollar spent on OTC medications saves the US healthcare system 7 dollars, or 146 million dollars annually (1). The majority of these cost savings come from reduced clinical visits as a result of OTC medications being readily available to the public. Making OTC medications tax-exempt would make these medications more accessible, thereby saving families and the healthcare system valuable dollars.

While a 5.5% tax may not seem like a prohibitive cost to some, for many Mainers struggling financially, that extra cost can mean the difference between affording an OTC medication and going without. We must ensure that every Mainer can afford the medications they need. OTC medications aren't a luxury, they're a necessity.

We urge the committee to vote "Ought to Pass" on LD 1734.

Thank you for your time and consideration.

Madeleine DesFosses Advocacy and Public Health Manager, Maine AAP

www.maineaap.org

^{**}Medical Student Representatives

Maine Chapter

INCORPORATED IN MAINE



References:

1. Consumer Healthcare Products Association. *Value of OTC Medicines to the U.S. Healthcare System*. March 2019. Accessed May 14, 2025. https://www.chpa.org/sites/default/files/media/docs/2020-10/Value-of-OTC-Medicines-to-the-US-Healthcare-System-03012019.pdf